Revenue
Q2.25
Q2.26
| Q2.26 | Q2.25 | |
|---|---|---|
| Revenue | $7.4M | $8.0M |
| Gross profit | $4.3M | $4.7M |
| Research & development | $3.7M | $4.5M |
| Operating expenses | $16.7M | $13.1M |
| Operating income | −$12.4M | −$8.4M |
| Net income | −$12.1M | −$8.2M |
| Basic EPSper diluted share | -$0.54 | -$0.38 |
| Diluted EPSper diluted share | -$0.54 | -$0.38 |
| Transaction | Insider | Type | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| Jun 18, 2026Form 4 | TCM Strategic Partners L.P. +2Other | SellCommon Stock · indirect | 27.1K | $9.46 | $256.1K | 0 |
| Jun 17, 2026Form 4 | TCM Strategic Partners L.P. +2Other | SellCommon Stock · indirect | 15.0K | $10.05 | $150.8K | 27.1K |
| Jun 16, 2026Form 4 | TCM Strategic Partners L.P. +2Other | SellCommon Stock · indirect | 3.5K | $10.96 | $38.5K | 0 |
| Jun 16, 2026Form 4 | TCM Strategic Partners L.P. +2Other | SellCommon Stock · indirect | 69.4K | $10.83 | $751.2K | 42.1K |